Pfizer Inc. $PFE Shares Bought by Trust Point Inc.

Trust Point Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 107.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,683 shares of the biopharmaceutical company’s stock after purchasing an additional 35,006 shares during the quarter. Trust Point Inc.’s holdings in Pfizer were worth $1,630,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Vermillion Wealth Management Inc. boosted its holdings in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the last quarter. Triad Wealth Partners LLC grew its holdings in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the period. Eagle Capital Management LLC increased its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. raised its holdings in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares during the period. Finally, Delta Financial Advisors LLC raised its holdings in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 398 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on PFE. Morgan Stanley raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Guggenheim decreased their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Better-than-expected Q2 results supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate and revenue of $15.03 billion versus expectations of $14.40 billion. The company also raised its 2026 revenue outlook, helping offset concerns about declining COVID-related sales. Pfizer Inc. Q2 2026 Earnings Call Summary
• Positive Sentiment: Pipeline progress is improving Pfizer’s longer-term outlook. Analysts highlighted the company’s broader pipeline, including the potential obesity treatment berobenatide and PF-07328948. Berobenatide is being compared with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, although Pfizer still faces significant development and competitive hurdles. Pfizer’s Next Weight-Loss Weapon
• Positive Sentiment: Pfizer and BioNTech advanced COVID-19 vaccine studies. A new Phase 4 study of a variant-adapted booster, along with progress on a next-generation pediatric booster, could support future vaccine demand and preserve the partnership’s commercial position. Variant-Adapted COVID-19 Booster Study
• Neutral Sentiment: Analyst opinion remains mixed. Some analysts are bullish after the earnings beat and pipeline updates, while RBC Capital maintained a Hold rating, indicating that valuation and execution risks continue to limit conviction. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: Patent expirations and obesity-program uncertainty remain overhangs. Investors are questioning whether Pfizer’s pipeline can replace revenue lost to upcoming patent cliffs, while previous obesity setbacks make the berobenatide opportunity particularly important but far from assured. Pfizer’s Patent and Pipeline Outlook
• Negative Sentiment: COVID product sales remain weak. Pfizer’s COVID pill revenue reportedly fell 95%, underscoring the company’s continuing dependence on non-COVID products and pipeline launches to drive growth. Pfizer COVID Pill Revenue Decline

Pfizer Stock Up 1.9%

NYSE:PFE opened at $26.70 on Friday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The firm has a market capitalization of $152.20 billion, a price-to-earnings ratio of 35.14 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average price is $25.02 and its two-hundred day moving average price is $26.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.